Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Profit After Tax: 2015-2024

Historic Profit After Tax for Intellia Therapeutics (NTLA) over the last 10 years, with Dec 2024 value amounting to -$519.0 million.

  • Intellia Therapeutics' Profit After Tax rose 25.34% to -$101.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$445.8 million, marking a year-over-year increase of 14.64%. This contributed to the annual value of -$519.0 million for FY2024, which is 7.86% down from last year.
  • Intellia Therapeutics' Profit After Tax amounted to -$519.0 million in FY2024, which was down 7.86% from -$481.2 million recorded in FY2023.
  • Intellia Therapeutics' 5-year Profit After Tax high stood at -$134.2 million for FY2020, and its period low was -$519.0 million during FY2024.
  • Moreover, its 3-year median value for Profit After Tax was -$481.2 million (2023), whereas its average is -$491.5 million.
  • Data for Intellia Therapeutics' Profit After Tax shows a maximum YoY crashed of 99.58% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Intellia Therapeutics' Profit After Tax stood at -$134.2 million in 2020, then plummeted by 99.58% to -$267.9 million in 2021, then slumped by 77.01% to -$474.2 million in 2022, then dropped by 1.48% to -$481.2 million in 2023, then dropped by 7.86% to -$519.0 million in 2024.